Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

A DUPLEX study investigator explains the data behind sparsentan's approval by the FDA. 

Why Sparsentan’s FDA Approval Marks a Turning Point in FSGS, With Howard Tratchman, MD

FDA fully approves sparsentan for FSGS, offering the first oral non-immunosuppressive option that targets podocyte injury and cuts proteinuria.

FDA Approves Sparsentan for Focal Segmental Glomerulosclerosis

An expert shares his perspective on emerging targets and precision strategies for podocyte injury in glomerular disease. 


Emerging Targets in Podocyte Injury Signal Shift in Glomerular Disease Treatment, With John Cijiang He, MD, PhD

Podocyte Injury Emerges as Central Driver of Progression in FSGS, Diabetic Kidney Disease

NEPTUNE and CureGN are advancing precision nephrology, linking molecular data to outcomes and enabling targeted therapies and smarter clinical trial design.

​​NEPTUNE and CureGN Driving Precision Nephrology Forward, With Alessia Fornoni, MD, PhD

FSGS recurrence threatens transplant success, yet clinicians still lack reliable predictors, mechanisms, and effective prevention strategies.

The Search for Answers in FSGS Recurrence, With Priya Verghese, MBBS (MD), MPH

Experts outline a 2026 vision for glomerular disease care, including new endpoints, combination therapies, and gene therapy advances.

Clinical Trial Summit 2026: Advanced Therapies, Equity, Global Outlook For Glomerular Diseases

The PARASOL initiative is reshaping glomerular disease trials through shared data and improved surrogate endpoints.

PARASOL, Endpoints, and Rethinking Clinical Trials in Glomerular Disease

PLA2R antibodies are advancing precision care in membranous nephropathy and informing new surrogate endpoints through PARASOL.

PLA2R, Membranous Nephropathy, and the PARASOL Membranous Project

Anti-nephrin autoantibodies are redefining minimal change disease and enabling more precise, steroid-sparing treatment strategies.

Anti-Nephrin Autoantibodies, Precision in Nephrotic Syndrome

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 